Transforming Health Through Cutting-Edge Research and Innovative Care
At Geistek Pharmaceuticals, we are committed to advancing the field of internal medicine and immunology to improve health outcomes for patients worldwide. With a focus on understanding the complexities of the human immune system and its role in various diseases, we strive to develop innovative therapies and diagnostic tools that revolutionize patient care.
Our expertise in internal medicine encompasses a wide range of conditions, including autoimmune diseases, rheumatology, gastroenterology, nephrology, pulmonology, and many others. We understand the unique challenges posed by these diseases and the impact they have on patients’ lives. Through cutting-edge research and development, we aim to provide effective treatments that address the underlying causes of these conditions and restore health and well-being.
Immunology is at the core of our research and development efforts. We are dedicated to unraveling the intricate mechanisms of the immune system and harnessing its potential to combat diseases. By understanding the immune response and its dysregulation in various conditions, we are able to develop targeted therapies that modulate the immune system and restore its balance.
At Geistek Pharmaceuticals, we have assembled a team of world-class scientists, researchers, and medical professionals who are passionate about advancing internal medicine and immunology. Through interdisciplinary collaboration and a patient-centric approach, we aim to translate scientific discoveries into meaningful therapies that make a real difference in patients’ lives.
We prioritize safety, efficacy, and accessibility in all our endeavors. Our commitment to rigorous clinical trials and regulatory compliance ensures that our therapies meet the highest standards of quality and are available to patients who need them most. We work closely with regulatory agencies and healthcare providers to ensure the seamless integration of our innovative therapies into clinical practice.
Geistek Pharmaceuticals is not just focused on treatment but also on prevention and early detection. We invest in research and development of diagnostic tools that aid in the early identification of diseases, allowing for timely intervention and improved outcomes. By understanding the disease process at its earliest stages, we can develop strategies to prevent or mitigate its progression.
We believe in the power of collaboration and partnerships to drive innovation in internal medicine and immunology. We actively collaborate with leading academic institutions, medical experts, and patient advocacy groups to foster knowledge exchange, promote research, and address unmet medical needs.
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
INTRODUCTION Kymriah (Novartis) is an advanced therapy medicine that belongs to the gene therapyproduct category. It is approved for B-cell acute lymphoblastic leukemia (ALL) in
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment
